NASDAQ:VKTX - Viking Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.44
  • Forecasted Upside: 147.28 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 1 Strong Buy Ratings
$6.65
▲ +0.1 (1.53%)
1 month | 3 months | 12 months
Get New Viking Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VKTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VKTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$16.44
▲ +147.28% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $16.44, with a high forecast of $27.00 and a low forecast of $12.00. The average price target represents a 147.28% upside from the last price of $6.65.
Buy
The current consensus among 10 contributing investment analysts is to buy stock in Viking Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2019
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2019
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/11/2020
  • 1 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/9/2020
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2020
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2020
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/4/2021
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/6/2021

Latest Recommendations

  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/22/2021Stifel NicolausReiterated RatingBuy$13.00Low
i
Rating by Derek Archila at Stifel Nicolaus
10/29/2020Raymond JamesBoost Price TargetStrong-Buy$25.00 ➝ $27.00Medium
i
9/11/2020William BlairReiterated RatingBuyLow
i
Rating by Andy Hsieh at William Blair
9/10/2020B. RileyReiterated RatingBuy$15.00High
i
Rating by Mayank Mamtani at B. Riley
9/1/2020BTIG ResearchBoost Price TargetBuy$9.00 ➝ $12.00High
i
8/31/2020Chardan CapitalBoost Price TargetBuy$15.00 ➝ $20.00Medium
i
Rating by Michael Morabito at Chardan Capital
8/28/2020HC WainwrightBoost Price TargetBuy$18.00 ➝ $21.00High
i
8/6/2020Raymond JamesReiterated RatingBuy$25.00Medium
i
7/30/2020B. RileyReiterated RatingBuy$12.00High
i
Rating by Mayank Mamtani at B. Riley
7/29/2020Chardan CapitalReiterated RatingBuy$15.00High
i
Rating by Michael Morabito at Chardan Capital
7/29/2020OppenheimerReiterated RatingBuy$12.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/29/2020Stifel NicolausReiterated RatingBuy$14.00High
i
Rating by Derek Archila at Stifel Nicolaus
6/4/2020BMO Capital MarketsInitiated CoverageOutperform$14.00Medium
i
5/5/2020Chardan CapitalInitiated CoverageBuy$15.00Medium
i
Rating by M. Morabito at Chardan Capital
5/4/2020B. RileyLower Price TargetBuy$16.00 ➝ $12.00High
i
Rating by Mayank Mamtani at B. Riley
5/2/2020Maxim GroupInitiated CoverageBuy$14.00High
i
Rating by Jason McCarthy at Maxim Group
5/1/2020OppenheimerInitiated CoverageBuy$12.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/1/2020Raymond JamesLower Price TargetStrong-Buy$41.00 ➝ $25.00High
i
5/1/2020BTIG ResearchInitiated CoverageBuy$9.00High
i
4/30/2020Stifel NicolausReiterated RatingBuy$14.00High
i
4/3/2020William BlairReiterated RatingBuyLow
i
Rating by Andy Hsieh at William Blair
3/18/2020William BlairReiterated RatingBuyHigh
i
Rating by Andy Hsieh at William Blair
2/27/2020HC WainwrightLower Price TargetBuy$31.00 ➝ $18.00High
i
1/2/2020SVB LeerinkReiterated RatingOutperformMedium
i
Rating by T. Smith at SVB Leerink LLC
11/21/2019B. RileyInitiated CoverageBuy$16.00Low
i
Rating by Mayank Mamtani at B. Riley
11/6/2019Maxim GroupReiterated RatingBuy$14.00Low
i
11/5/2019HC WainwrightReiterated RatingBuy$31.00High
i
8/2/2019HC WainwrightReiterated RatingBuy$31.00High
i
Rating by J. Pantginis at HC Wainwright
7/16/2019CIBCInitiated CoverageOutperform ➝ Outperform$12.00Low
i
7/16/2019OppenheimerInitiated CoverageOutperform$12.00 ➝ $12.00High
i
7/15/2019CitigroupInitiated CoverageOutperformHigh
i
6/25/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$14.00High
i
4/11/2019HC WainwrightReiterated RatingBuy$31.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
3/29/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$10.00 ➝ $21.00High
i
Rating by P. Sarraf at SVB Leerink LLC
3/29/2019William BlairReiterated RatingOutperformHigh
i
Rating by Andy Hsieh at William Blair
3/14/2019Raymond JamesLower Price TargetStrong-Buy ➝ Strong-Buy$43.00 ➝ $40.00Low
i
Rating by Steven Seedhouse at Raymond James
3/14/2019William BlairReiterated RatingOutperformHigh
i
Rating by Andy Hsieh at William Blair
3/14/2019Maxim GroupLower Price TargetBuy$28.00 ➝ $20.00High
i
2/22/2019SVB LeerinkInitiated CoverageMarket Perform$10.00Medium
i
12/11/2018B. RileyInitiated CoverageBuy ➝ Buy$16.00Low
i
Rating by Mayank Mamtani at B. Riley
11/19/2018Raymond JamesUpgradeOutperform ➝ Strong-Buy$43.00High
i
Rating by Steven Seedhouse at Raymond James
11/13/2018William BlairReiterated RatingBuyHigh
i
Rating by Andy Hsieh at William Blair
11/9/2018Roth CapitalSet Price TargetBuy$23.00Medium
i
Rating by Scott Henry at Roth Capital
11/8/2018Maxim GroupReiterated RatingBuy$28.00High
i
11/8/2018HC WainwrightReiterated RatingBuy$31.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
10/1/2018William BlairReiterated RatingMarket PerformHigh
i
Rating by A. Hsieh at William Blair
10/1/2018HC WainwrightSet Price TargetBuy$31.00High
i
Rating by Joseph Pantginis at HC Wainwright
9/19/2018Raymond JamesSet Price TargetBuy$43.00Low
i
Rating by Steven Seedhouse at Raymond James
9/19/2018Roth CapitalBoost Price TargetBuy$13.00 ➝ $24.00High
i
9/19/2018SunTrust BanksBoost Price TargetBuy$28.00High
i
9/18/2018Maxim GroupReiterated RatingBuy ➝ Buy$14.00 ➝ $28.00High
i
Rating by Jason McCarthy at Maxim Group
9/18/2018Raymond JamesReiterated RatingOutperform ➝ Outperform$15.00 ➝ $43.00High
i
Rating by Steven Seedhouse at Raymond James
9/18/2018HC WainwrightSet Price TargetBuy ➝ Buy$15.00 ➝ $28.00High
i
Rating by Joseph Pantginis at HC Wainwright
8/10/2018William BlairReiterated RatingOutperformHigh
i
Rating by A. Hsieh at William Blair
8/10/2018HC WainwrightReiterated RatingBuy$15.00High
i
Rating by Joseph Pantginis at HC Wainwright
7/20/2018SunTrust BanksInitiated CoverageBuy$14.00High
i
6/28/2018Raymond JamesInitiated CoverageOutperform$15.00Medium
i
6/1/2018Roth CapitalBoost Price TargetBuy$7.50 ➝ $13.00Low
i
Rating by Scott Henry at Roth Capital
6/1/2018LaidlawBoost Price TargetBuy$10.00 ➝ $15.00High
i
6/1/2018HC WainwrightBoost Price TargetBuy ➝ Buy$11.00 ➝ $15.00High
i
Rating by Joseph Pantginis at HC Wainwright
5/31/2018Maxim GroupReiterated RatingBuy ➝ Buy$8.00 ➝ $14.00High
i
Rating by Jason McCarthy at Maxim Group
5/10/2018HC WainwrightSet Price TargetBuy$11.00High
i
Rating by Joseph Pantginis at HC Wainwright
5/10/2018Maxim GroupSet Price TargetBuy$8.00High
i
Rating by Jason McCarthy at Maxim Group
4/30/2018William BlairInitiated CoverageOutperformLow
i
Rating by A. Hsieh at William Blair
3/26/2018HC WainwrightReiterated RatingBuy ➝ Buy$11.00High
i
Rating by Joseph Pantginis at HC Wainwright
3/8/2018Roth CapitalSet Price TargetBuy$8.00High
i
Rating by Scott Henry at Roth Capital
3/8/2018Maxim GroupReiterated RatingBuy$8.00High
i
Rating by Jason McCarthy at Maxim Group
2/2/2018Maxim GroupReiterated RatingBuy$8.00Low
i
Rating by Jason McCarthy at Maxim Group
12/12/2017Maxim GroupSet Price TargetBuy$8.00Low
i
Rating by Jason McCarthy at Maxim Group
11/29/2017Roth CapitalSet Price TargetBuy$6.00High
i
Rating by Scott Henry at Roth Capital
11/28/2017Maxim GroupSet Price TargetBuy$5.00 ➝ $8.00High
i
Rating by Jason McCarthy at Maxim Group
11/21/2017Roth CapitalInitiated CoverageBuy ➝ Buy$5.00N/A
i
Rating by S. Henry at Roth Capital
11/10/2017HC WainwrightReiterated RatingBuy ➝ Buy$7.00N/A
i
Rating by E. Arce at HC Wainwright
10/4/2017Maxim GroupReiterated RatingBuy$5.00N/A
i
Rating by Jason McCarthy at Maxim Group
9/11/2017Maxim GroupReiterated RatingBuy$5.00High
i
Rating by Jason McCarthy at Maxim Group
8/10/2017Maxim GroupSet Price TargetBuy$5.00High
i
Rating by Jason McCarthy at Maxim Group
7/17/2017HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $7.00Low
i
6/6/2017Maxim GroupSet Price TargetBuy$5.00Low
i
Rating by Jason McCarthy at Maxim Group
5/11/2017Maxim GroupReiterated RatingBuy$5.00High
i
Rating by Jason McCarthy at Maxim Group
3/27/2017HC WainwrightReiterated RatingBuy$5.00Medium
i
3/22/2017Maxim GroupSet Price TargetBuy$5.00Medium
i
Rating by Jason McCarthy at Maxim Group
2/11/2017Maxim GroupSet Price TargetBuy$5.00N/A
i
Rating by Jason McCarthy at Maxim Group
12/7/2016Maxim GroupSet Price TargetBuy$5.00N/A
i
Rating by Jason McCarthy at Maxim Group
11/11/2016Maxim GroupSet Price TargetBuy$5.00N/A
i
Rating by Jason McCarthy at Maxim Group
10/25/2016Maxim GroupSet Price TargetBuy$5.00N/A
i
Rating by Jason McCarthy at Maxim Group
9/18/2016HC WainwrightReiterated RatingBuy$6.00N/A
i
Rating by Carol Werther at HC Wainwright
8/11/2016Maxim GroupSet Price TargetBuy$5.00N/A
i
Rating by jason mccarthy at Maxim Group
8/11/2016LaidlawLower Price TargetBuy$20.00 ➝ $10.00N/A
i
5/24/2016Maxim GroupInitiated CoverageBuy$5.00N/A
i
4/7/2016HC WainwrightInitiated CoverageBuy$6.00N/A
i
Rating by C. Werther at HC Wainwright
(Data available from 3/7/2016 forward)
Viking Therapeutics logo
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $6.65
$6.04
$6.65

50 Day Range

MA: $7.57
$6.48
$9.67

52 Week Range

Now: $6.65
$3.26
$10.09

Volume

1,376,651 shs

Average Volume

1,625,807 shs

Market Capitalization

$492.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.02

Frequently Asked Questions

What sell-side analysts currently cover shares of Viking Therapeutics?

The following Wall Street sell-side analysts have issued reports on Viking Therapeutics in the last twelve months: B. Riley, BMO Capital Markets, BTIG Research, Chardan Capital, HC Wainwright, Maxim Group, Oppenheimer Holdings Inc., Raymond James, Stifel Nicolaus, William Blair, and Zacks Investment Research.
View the latest analyst ratings for VKTX.

What is the current price target for Viking Therapeutics?

9 Wall Street analysts have set twelve-month price targets for Viking Therapeutics in the last year. Their average twelve-month price target is $16.44, suggesting a possible upside of 147.3%. Raymond James has the highest price target set, predicting VKTX will reach $27.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $12.00 for Viking Therapeutics in the next year.
View the latest price targets for VKTX.

What is the current consensus analyst rating for Viking Therapeutics?

Viking Therapeutics currently has 9 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VKTX will outperform the market and that investors should add to their positions of Viking Therapeutics.
View the latest ratings for VKTX.

What other companies compete with Viking Therapeutics?

How do I contact Viking Therapeutics' investor relations team?

Viking Therapeutics' physical mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company's listed phone number is 858-704-4660 and its investor relations email address is [email protected] The official website for Viking Therapeutics is www.vikingtherapeutics.com.